Clinical trials: Acute Phase
Acute Myeloid Leukemia
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
The purpose of this study is to determine the tolerated dose of the combination of decitabine and midostaurin as induction (first cycle of chemotherapy) and consolidation (additional chemotherapy once a patient goes into…
- Trial name
- NCT01130662
- Testing
- combination therapy using decitabine and midostaurin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Kansas
Thoracic Aortic Aneurysms, and Penetrating Atherosclerotic Ulcers
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
The purpose of this study is to evaluate the safety and efficacy of the Relay thoracic stent-graft system to treat thoracic aortic aneurysms.
- Trial name
- NCT00435942
- Testing
- Relay Thoracic Stent-Graft, Open Repair
- Where
- 27 sites in United States
- Volunteers
- 180 people
- Sponsor
- Bolton Medical
Acute Myeloid Leukemia
Alvocidib Biomarker-driven Phase 2 AML Study
The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete Remission) of ACM (Alvocidib/Cytarabine/Mitoxantrone) compared to CM (Cytarabine/Mitoxantrone) treatment in refractory or relapsed AML…
- Trial name
- NCT02520011
- Testing
- Alvocidib, Cytarabine, Mitoxantrone
- Where
- 38 sites in United States, Canada and 2 more
- Volunteers
- 104 people
- Sponsor
- Sumitomo Pharma America, Inc.
SARS Virus
Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia
Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach.
- Trial name
- POLYCOR (NCT04453384)
- Testing
- XAV-19
- Where
- 34 sites in France, Martinique and 1 more
- Volunteers
- 416 people
- Sponsor
- Nantes University Hospital
B-cell Acute Lymphoblastic Leukemia
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045.
- Trial name
- NCT07570173
- Testing
- MK-1045, Blinatumomab, Acetaminophen
- Where
- 28 sites in Canada, Denmark and 8 more
- Volunteers
- 340 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
Study of Sequential CAR-T Cell Treating Leukemia Children
The investigators will conduct a phase II clinical trial of sequential chimeric antigen receptor T cell targeting at different B-cell antigens in refractory or relapsed B-cell acute lymphoblastic leukemia children in Beijing…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia
- Trial name
- NCT04340154
- Testing
- chimeric antigen receptor T cell
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Beijing Boren Hospital
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
Body Composition, Beneficial, Oxidative Stress
Phase Angle and Body Composition, Inflammatory and Oxidative Stress Biomarkers.
The main purpose of the present study was to investigate the effects of 12 weeks of resistance training (RT) on phase angle (PhA), body composition, inflammatory and oxidative stress biomarkers, in older women and to evaluate…
- Conditions
- Body Composition, Beneficial, Oxidative Stress, Acute and Chronic Inflammation
- Trial name
- NCT02940145
- Testing
- Resistance Training
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Universidade Estadual de Londrina
Acute Myeloid Leukemia
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
To learn if adding a healthy person's natural killer (NK) cells to the combination of Azacitidine and Venetoclax can help to control AML. NK cells are cancer- and infection-fighting immune cells.
- Trial name
- NCT05834244
- Testing
- Azacitidine, Venetoclax, NK Cells
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Acute Myelogenous
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia
This is an open label phase I clinical trial of hydroxychloroquine (HCQ) ,when it is combined with the usual medications for acute myeloid leukemia, mitoxantrone and etoposide.
- Trial name
- NCT02631252
- Testing
- Hydroxychloroquine, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Alison Sehgal, MD, MS
Acute Leukemia
Hematotoxicity in Acute Lymphoblastic Leukemia Children in Maintenance Phase Therapy
This study use an observational study design from patient medical records to obtain data on patient demographics, nutritional status, 6MP dosing, and albumin levels of LLA child patients.
- Trial name
- NCT03279900
- Where
- Indonesia
- Volunteers
- 101 people
- Sponsor
- Universitas Indonesia
AML, Acute Myeloid Leukemia
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
A primary goal of this clinical research study is to find the highest safe dose of sorafenib that can be given in combination with idarubicin and Ara-C for the treatment of acute myelogenous leukemia (AML) and high-risk…
- Conditions
- AML, Acute Myeloid Leukemia, Myelodysplastic Disorders
- Trial name
- NCT00542971
- Testing
- Idarubicin, Sorafenib, Ara-C
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has IDH1 mutation.
- Conditions
- Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT04493164
- Testing
- Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
AML
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
The study is a multicenter, open label Phase I/II trial. 1. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion) 2.
- Trial name
- NCT02575963
- Testing
- Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only)
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 40 people
- Sponsor
- Actinium Pharmaceuticals
Acute Coronary Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT01004406)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- VA Office of Research and Development
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This phase II trial studies the side effects and how well giving combination chemotherapy together with dasatinib works in treating patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Trial name
- NCT01238211
- Testing
- Cytarabine, Dasatinib, Daunorubicin Hydrochloride
- Where
- 65 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Intracranial Hemorrhages
Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage
The overall goal is to establish the safety and efficacy of colchicine in ICH patients for the prevention of major cardiovascular events and brain injury.
- Trial name
- CoVasc-ICH (NCT05159219)
- Testing
- Colchicine Pill
- Where
- 11 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Population Health Research Institute
T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma
A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
This is a clinical research study for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The study will test a new treatment called "autologous nano CD5-CAR T cells".
- Conditions
- T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma, Relapsed/Refractory Hematologic Malignancies
- Trial name
- NCT07678307
- Testing
- Autologous nano CD5-CAR T Cells
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy, such as cladribine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258271
- Testing
- filgrastim, cladribine, cytarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Rochester
COVID-19
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
This study is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of FB2001 in hospitalized patients with moderate to severe Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT05445934
- Testing
- FB2001
- Where
- 2 sites in China
- Volunteers
- 1,188 people
- Sponsor
- Frontier Biotechnologies Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.